CAR-M therapies directed against HER2 and EGFRvIII improved survival in preclinical models and are anticipated to cross the blood–brain barrier, while IL-13Rα2 and mesothelin have been validated as potential targets for brain tumor eradication. This evidence concerns the gene MSLN and brain neoplasm.